Understanding stem cell therapy — a primer.

Stem cell therapy gets talked about as either miracle cure or experimental snake oil. The reality sits somewhere in between, and where exactly depends entirely on what you're treating, who's treating it, and which kind of stem cells they're using.

This is a plain-language primer on stem cell therapy — what it is, how it actually works, and what the published clinical evidence shows. No marketing language, real citations, and an honest account of where the evidence is solid and where it is still emerging.

What stem cells actually are

Stem cells are unspecialised cells that can divide and become other cell types. Your body uses them constantly — to heal cuts, replace blood cells, regenerate the lining of your gut. They are, in the most literal sense, your repair workforce.

The catch: by the time you're 80, you have only a tiny fraction of the active stem cells you started with. Studies of bone-marrow-derived mesenchymal stem cells (MSCs) document orders-of-magnitude declines with age — the frequency drops from roughly one in ten thousand at birth to around one in two million by age 80.^[1] That's not a typo. Two hundred-fold less.

This is part of why ageing feels like ageing. Your repair crew is shrinking.

How they actually work — three modes

When stem cells are introduced to the body, they do three things:

• Replace. They can differentiate into damaged tissue — cartilage, muscle, neurons, skin.
• Renew. They divide and repopulate, increasing the local count of healthy cells.
• Signal. They release growth factors, cytokines, and exosomes that tell surrounding cells to behave better — calm down inflammation, repair, regenerate.

Here's the part most marketing skips: the third mechanism — paracrine signalling — is now considered the primary therapeutic mechanism for most current MSC treatments. In a 2017 paper, Arnold Caplan, who originally named MSCs, formally proposed renaming them "Medicinal Signaling Cells" because most of the benefit isn't direct cell replacement.^[2] It's the cells telling your body to do better work.

Where they come from — autologous vs allogeneic

Two categories are used clinically:

Autologous (your own cells)

Cells are harvested from your own body — most commonly from adipose (fat) tissue. Japanese protocols often use a small post-auricular harvest behind the ear, performed under local anaesthesia in around 15 minutes. The cells are then cultured in a GMP-compliant laboratory for roughly a month before being infused back. Tailored to you, slower, no rejection risk.

Allogeneic (donor cells)

Cells come from a donor — most commonly Wharton's jelly from donated umbilical cords. They're pre-cultured, available immediately, and have a very low rejection risk because cord-derived MSCs have minimal MHC-II expression — the immune-system markers your body would attack.^[3] Single visit, faster turnaround.

The choice between them is mostly about time and personalisation. We unpack it in detail in a separate article.

What we know vs what we hope

The honest answer is: it depends on the condition. Three buckets of evidence.

Strong evidence

Cord-blood transplant for blood disorders has been FDA-approved since 2011 (Hemacord).^[4] Knee osteoarthritis has multiple randomised trials and systematic reviews showing meaningful pain and function improvement.^[5] Graft-versus-host disease is well established. These aren't experimental anymore.

Emerging evidence

Type 2 diabetes shows promising results in published RCTs — including significant improvements in glycemic control and insulin requirements after MSC therapy.^[6] Cardiovascular and neurodegenerative disease have early but real positive signal. Not yet definitive, but not anecdotal either.

Uncertain

Facial rejuvenation, sexual health, generic "longevity benefit." Lots of clinic marketing here. Very limited rigorous evidence. If you're being sold this, ask hard questions.

What to ask before treatment

Five questions every reputable clinic should be able to answer in writing:

1. Which evidence bucket is my condition in? If they can't tell you, walk.
2. Which authority licenses your protocol? Show me the paperwork. (MHLW in Japan, NPRA in Malaysia, FDA in the US.)
3. Where are the cells processed and to what standard? Look for ISO Class 5 cleanrooms and PIC/S GMP — the international pharmaceutical-manufacturing standard.
4. Has your safety data been published? Where? In which journal?
5. What's the realistic timeline and total cost — itemised?

The clinics that answer these directly are the ones worth working with.

The bottom line

Stem cell therapy is real, regulated, and increasingly well-studied. It's also surrounded by marketing claims that run far ahead of the evidence. The gap between strong evidence and aspirational claims is wide. Read carefully. Ask hard questions. Most of the upside is in the conditions where the data is already strong — and the rest is a more speculative bet you should make with your eyes open.

Sources

1. Stolzing A, Jones E, McGonagle D, Scutt A. (2008) "Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies." Mech Ageing Dev 129(3):163-73.
2. Caplan AI. (2017) "Mesenchymal Stem Cells: Time to Change the Name!" Stem Cells Transl Med 6(6):1445-51.
3. Le Blanc K, Mougiakakos D. (2012) "Multipotent mesenchymal stromal cells and the innate immune response." Nat Rev Immunol 12(5):383-96.
4. U.S. Food and Drug Administration. (10 November 2011) News Release: "FDA approves first stem cell product, Hemacord."
5. Pas HI, Winters M, Haisma HJ, Koenis MJ, Tol JL, Moen MH. (2017) "Stem cell injections in knee osteoarthritis: a systematic review of the literature." Br J Sports Med 51(15):1125-1133.
6. Cai J, Wu Z, Xu X, Liao L, Chen J, Huang L, Wu W, Luo F, Wu C, Pugliese A, Pileggi A, Ricordi C, Tan J. (2016) "Umbilical cord mesenchymal stromal cell with autologous bone marrow cell transplantation in established type 2 diabetes." Cell Transplant 25(8):1521-32.